The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Fisher & Paykel Healthcare's Revenue for the
six
months ended in Mar. 2026 was $706 Mil. Fisher & Paykel Healthcare's average Accounts Receivable for the
six
months ended in Mar. 2026 was $176 Mil.
Hence, Fisher & Paykel Healthcare's Receivables Turnover for the
six
months ended in Mar. 2026 was 4.01.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Fisher & Paykel Healthcare Receivables Turnover Related Terms
Fisher & Paykel Healthcare Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSPKF vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (FSPKF) has a Receivables Turnover of 4.01 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Fisher & Paykel Healthcare and its competitors. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #190 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 23.4%.
Is Fisher & Paykel Healthcare's Receivables Turnover too high?
Fisher & Paykel Healthcare's current Receivables Turnover is 4.01. The Medical Devices & Instruments industry median Receivables Turnover is 5.55. Fisher & Paykel Healthcare's value of 4.01 is 27.7% below this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #190 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #190 out of 811 companies for Receivables Turnover. This places Fisher & Paykel Healthcare in the top 23% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.55. Fisher & Paykel Healthcare's value of 4.01 is 27.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.55, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Receivables Turnover of 4.01 is 27.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Receivables Turnover is 4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.31, compared to a current price of $22.52 — trading 17.5% below its estimated fair value. The current Receivables Turnover is 4.01 and 27.7% below the Medical Devices & Instruments industry median of 5.55. Fisher & Paykel Healthcare's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current Receivables Turnover is 4.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of $22.52 is trading 17.5% below its estimated GF Value™ of $27.31.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for FSPKF:
Receivables Turnover: 4.01
GF Value™: $27.31 vs. price of $22.52 (17.5% below fair value)
Industry Position: 27.7% below the Medical Devices & Instruments median (#190 of 811)
No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
91GF Score
Get the complete analysis for FSPKF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSPKF has been successfully added to your 
